Related by context. All words. (Click for frequent words.) 73 metastatic malignant 73 relapsed MM 73 leukemia AML 71 ara C 71 Fludarabine 71 lymphoid malignancies 71 small lymphocytic lymphoma 70 papillary renal cell carcinoma 70 recurrent glioblastoma multiforme 70 bendamustine 69 CHOP chemotherapy 69 dasatinib Sprycel ® 69 multiple myeloma MM 69 pT3 69 fluorouracil leucovorin 69 Tarceva TM 69 galiximab 68 Pharmacokinetics PK 68 KRAS mutations occur 68 lymphocytosis 68 T1c 68 Doxil ® 68 treatment naive genotype 68 metastatic malignant melanoma 68 non splenectomized 68 estramustine 68 mRCC 68 HBeAg negative 68 demonstrated antitumor activity 68 underwent surgical resection 68 Amrubicin 68 pT2 68 pegylated liposomal doxorubicin 68 dose cohort 68 relapsed refractory 68 azacytidine 68 neoadjuvant treatment 68 ZACTIMA 68 dasatinib Sprycel 68 histone deacetylase HDAC inhibitor 68 BARACLUDE ® 68 Chronic Lymphocytic Leukemia CLL 68 pediatric acute lymphoblastic 68 Diffuse Large B 68 certolizumab 68 follicular lymphoma FL 67 doxorubicin cyclophosphamide 67 mg/m2 dose 67 fludarabine cyclophosphamide 67 adalimumab Humira 67 sunitinib Sutent 67 platinum refractory 67 PEG IFN 67 metastatic GIST 67 achieved ACR# 67 gemcitabine cisplatin 67 B Cell Lymphoma 67 receptor tyrosine kinase inhibitor 67 haematologic malignancies 67 CsA 67 essential thrombocythemia ET 67 heavily pretreated 67 gastrointestinal stromal tumor GIST 67 histologically confirmed 67 receiving highly emetogenic 67 NMIBC 67 stage IIIb IV 67 refractory chronic lymphocytic 67 8mg/kg 67 Glioblastoma Multiforme 67 Pemetrexed 67 Folfox 67 Retreatment 67 Ozarelix 67 chemoradiotherapy 67 placebo dexamethasone 67 oblimersen 67 EGFR HER2 67 Myelodysplastic Syndrome MDS 67 gemcitabine carboplatin 67 hepatorenal syndrome 67 melphalan prednisone 67 Vitaxin 67 leukemia CLL 67 chronic lymphocytic leukemia CLL 67 Follicular Lymphoma 67 huN# DM1 67 metastatic renal cell carcinoma 67 novel histone deacetylase 67 hepatocellular carcinomas 67 refractory NSCLC 67 Hycamtin ® 67 thalidomide Thalomid 67 IFN α 67 stage IIIB 66 5-FU/LV 66 beta 1a 66 undetectable HBV DNA 66 squamous cell carcinoma SCC 66 mg qd 66 mitoxantrone plus 66 carboplatin paclitaxel 66 chlorambucil 66 micafungin 66 fluoropyrimidine 66 dasatinib 66 CML CP 66 tumors GIST 66 comparator arm 66 Flu Cy 66 daily subcutaneous injections 66 achieved CCyR 66 dosing cohort 66 Toxicities 66 completely resected 66 4mg/kg 66 metastatic hormone refractory 66 anthracycline containing 66 antibody MAb 66 anthracycline taxane 66 DLBCL 66 splenectomized 66 cell lymphoma CTCL 66 Acute Myeloid Leukaemia AML 66 FluCAM arm 66 dacarbazine DTIC 66 refractory AML 66 metastatic colorectal 66 brivanib 66 Gleevec resistant 66 imatinib Gleevec ® 66 previously untreated follicular 66 MGd 66 prucalopride 66 Cutaneous T 66 liposomal amphotericin B 66 relapsed refractory multiple myeloma 66 CCyR 66 histologic subtype 66 CTAP# Capsules 66 BCIRG 66 refractory acute myeloid 66 selective phosphodiesterase 66 unresectable stage 66 Interferon alfa 66 prostate carcinoma 66 dose melphalan 66 CRp 66 atazanavir ritonavir 66 HCV RESPOND 2 66 resectable pancreatic cancer 66 AZT zidovudine Retrovir 66 caspofungin 66 seropositive patients 66 Paraplatin ® 66 anthracyclines taxanes 66 clodronate 66 baminercept 66 AVONEX ® 66 alkylating agent 66 mycophenolate mofetil 66 familial amyloidotic polyneuropathy FAP 65 HBeAg negative patients 65 taxane resistant 65 ritonavir boosted 65 Xelox 65 mCRC patients 65 SPRYCEL ® 65 heavily pretreated patients 65 Glypromate 65 metastatic pancreatic 65 peginterferon alpha 2a 65 advanced hepatocellular carcinoma 65 breast carcinoma 65 Platinol ® 65 heFH 65 haematologic 65 epithelial tumors 65 MALT lymphoma 65 recurrent NSCLC 65 tumor xenograft models 65 Bezielle 65 prior chemotherapy regimens 65 Fludara 65 imatinib therapy 65 pan HDAC inhibitor 65 partial remissions 65 gefitinib Iressa 65 receiving prophylactic anticoagulation 65 concurrent chemoradiation 65 ertapenem 65 HBeAg positive patients 65 nonmetastatic 65 Hormone Refractory Prostate Cancer 65 pain palliation 65 biliary tract cancer 65 calcineurin inhibitor 65 LHRH receptor positive 65 SCCHN 65 biologic DMARD 65 hematologic toxicity 65 relapsed follicular 65 Enzastaurin 65 baseline LDH 65 castrate resistant 65 CYT# potent vascular disrupting 65 histological subtype 65 #mg BID [001] 65 relapsed CLL 65 Omacetaxine 65 mitoxantrone chemotherapy 65 myeloproliferative diseases 65 Multiple Myeloma MM 65 MDS AML 65 eosinophilic asthma 65 acute GvHD 65 OHR/AVR# 65 CTEPH 65 Navelbine ® 65 deep venous thromboses 65 locoregional recurrence 65 FOLFIRI alone 65 monoclonal antibody conjugated 65 K ras mutations 65 NSABP B 65 ibritumomab tiuxetan 65 systemic ALCL 65 mg kg dose 65 follicular lymphomas 65 Dacogen decitabine 65 Castration Resistant Prostate Cancer 65 HBeAg positive 65 docetaxel cisplatin 65 severe oral mucositis 65 HBeAg + 65 Irinotecan 65 biochemical relapse 65 dose dexamethasone 65 grade cervical intraepithelial 65 Epratuzumab 65 immune thrombocytopenic purpura ITP 65 imatinib Gleevec 65 refractory CLL 65 aurora kinase 65 GOUT 65 hA# 65 lymphoma subtypes 65 refractory cutaneous T 65 myelodysplastic myeloproliferative diseases 65 gemcitabine Gemzar ® 65 cytogenetic responses 65 MELAS 65 alefacept 65 GW# [003] 65 goserelin 65 elevated transaminases 65 mL/min/#.# m 2 65 Pegylated Interferon 65 6 mercaptopurine 65 polycythemia vera essential thrombocythemia 65 daunorubicin 65 SSc patients 65 Aflibercept 65 cyclophosphamide doxorubicin vincristine 65 bleomycin 65 chemoradiation therapy 65 CIMZIA TM certolizumab pegol 65 stage IIIb 65 mcg albinterferon alfa 2b 65 depsipeptide 65 leukemia ALL 65 atypical hemolytic uremic syndrome 65 lymphoproliferative disorders 65 TNF antagonist 65 non Hodgkin lymphomas 64 ceftazidime 64 adriamycin 64 HoFH 64 Neulasta ® 64 liposomal doxorubicin 64 MabThera Rituxan 64 pheochromocytoma 64 Phase Ib clinical 64 acute myeloid 64 Degarelix 64 alpha 2a 64 Dasatinib 64 Mantle Cell Lymphoma 64 allogeneic hematopoietic stem cell 64 cetuximab Erbitux R 64 metastatic gastric 64 Velcade bortezomib 64 pomalidomide 64 Phase Ib Clinical Trial 64 cyclophosphamide methotrexate 64 ISTODAX ® 64 urothelial 64 recurrent malignant glioma 64 cis retinoic acid 64 mitomycin 64 cutaneous T 64 unfractionated heparin UFH 64 treatment naïve genotype 64 recurrent metastatic 64 CIMZIA TM 64 cancer mCRC 64 metastatic CRC 64 #mg/m# [001] 64 AKT inhibitor 64 elotuzumab 64 posaconazole 64 novel VDA molecule 64 mcg BID 64 KRAS wild 64 5 fluorouracil leucovorin 64 relapsed ALL 64 pegylated interferon alpha 64 HER2 positive metastatic breast 64 selective agonist 64 hypereosinophilic syndrome 64 VELCADE melphalan 64 ® lenalidomide 64 PegIFN RBV 64 PAOD 64 mg/m2/day 64 satraplatin Phase 64 Copegus ribavirin 64 TASKi3 64 Cell Lymphoma 64 epoetin alpha 64 Hodgkin lymphoma HL 64 underwent resection 64 pamidronate 64 metastatic neuroendocrine tumors 64 piperacillin tazobactam 64 HCV Genotype 64 gastrointestinal toxicities 64 Non Hodgkin 64 evaluable subjects 64 chronic eosinophilic leukemia 64 mCRPC 64 follicular Non Hodgkin 64 rFVIIa 64 renal cell carcinomas 64 ovarian carcinoma 64 Campath alemtuzumab 64 bladder carcinoma 64 median survivals 64 IGF 1R inhibitor 64 recurrent GBM 64 oral vancomycin 64 tigecycline 64 CIMZIA ™ 64 erlotinib Tarceva ® 64 etanercept Enbrel 64 ULORIC 64 lumiliximab 64 volociximab 64 FOLPI 64 urothelial carcinoma 64 cutaneous squamous cell carcinoma 64 Parathyroid Hormone 64 ongoing Phase 1b 64 Epirubicin 64 Soft Tissue Sarcoma 64 differentiated thyroid 64 Cytoxan 64 Prolongs Survival 64 PSMA ADC 64 Peginterferon 64 hormone refractory metastatic prostate 64 ug dose 64 orally administered inhibitor 64 severe neutropenia 64 abacavir Ziagen 64 Camptosar ® 64 Gleevec imatinib mesylate 64 indolent NHL 64 vincristine doxorubicin 64 recurrent glioblastoma 64 complete cytogenetic response 64 Janus Kinase 64 low dose cytarabine 64 HGPIN 64 macroglobulinemia 64 histologies 64 elevated LDH 64 abacavir lamivudine 64 liver histology 64 sorafenib Nexavar 64 investigational immunotherapy 64 Phase III randomized controlled 64 QTcF 64 Initiate Phase 64 fluconazole resistant 64 refractory colorectal cancer 64 mycophenolate mofetil MMF 64 lenalidomide Revlimid R 64 cisplatin gemcitabine 64 oral diclofenac 64 Decitabine 64 Squamous 64 FUSILEV enhances 64 metastatic bladder 64 Dacogen injection 64 HCV SPRINT 64 ß blockers 64 AEGR 64 nucleotide analog 64 alemtuzumab treated 64 osteosarcomas 64 MCyR 64 Angiotensin Converting Enzyme 64 dexamethasone Decadron 64 mouse xenograft models 64 Immunohistochemical staining 64 genotypic resistance 64 fosbretabulin 64 sunitinib malate 64 splenectomized patients 64 Ph + 64 5 Fluorouracil 64 verteporfin 64 cisplatin chemotherapy 64 FOLFOX6 64 Quinamed 64 Nilotinib 64 standard chemotherapy regimen 64 non resectable 64 Ishak fibrosis score 64 squamous histology 64 sargramostim 64 Peginterferon alfa 2b 64 microgram kg 64 lenalidomide dexamethasone 64 ErbB2 positive 64 alfa 2a 64 phase IIb study 64 Infusion Reactions Severe 64 DEB# 64 advanced adenomas 64 PPAR gamma agonist 63 multicenter randomized controlled 63 flutamide 63 nab paclitaxel 63 Relapsed Refractory 63 EGFR mutation positive 63 taxane chemotherapy 63 skeletal metastases 63 ribavirin RBV 63 briakinumab 63 adjunctive placebo 63 Vidaza azacitidine 63 relapsed acute lymphoblastic 63 acute leukemias 63 assessing T DM1 63 intravesical therapy 63 unresectable 63 pancreatic adenocarcinoma 63 invasive ductal 63 Adjuvant chemotherapy 63 Leukemias 63 somatostatin analog 63 Leucovorin 63 precursor acute lymphoblastic 63 imatinib resistant 63 fallopian tube carcinoma 63 taxane refractory 63 ARB telmisartan 63 dose escalation clinical 63 crizotinib PF # 63 paclitaxel carboplatin 63 docetaxel Taxotere ® 63 Stage IIB 63 forodesine 63 Interferon Alfa 63 malignant ascites 63 invasive candidiasis 63 relapsing multiple sclerosis 63 serum cortisol 63 null responder HCV 63 Waldenstrom macroglobulinemia 63 oral clodronate 63 BEACOPP 63 cytoreductive nephrectomy 63 paricalcitol 63 gastrointestinal stromal tumors GISTs 63 oral Hycamtin 63 MKC# MT 63 tyrosine kinase inhibitor TKI 63 lintuzumab SGN 63 Azacitidine 63 Aplidin 63 INCB# [003] 63 humanised monoclonal antibody 63 Papillary 63 Traficet EN 63 Ibritumomab Tiuxetan 63 ACTEMRA TM 63 superficial bladder cancer 63 CALGB # [002] 63 Pathway Inhibitor 63 dornase alfa 63 relapsed Acute Myeloid 63 gemtuzumab ozogamicin 63 TO AVOID PREGNANCY WHILE 63 docetaxel Taxotere R 63 uM 63 CANCIDAS 63 prokinetic agent 63 LEXIVA r 63 radiotherapy RT 63 thymoma 63 antiretroviral naïve 63 Teriflunomide 63 postoperative chemotherapy 63 relapsed acute myelogenous 63 colorectal adenoma 63 MAGE A3 ASCI 63 anastrazole 63 pulmonary metastases 63 nilotinib 63 mg p = 63 Subgroup analysis 63 rapid virologic response 63 immunoconjugate 63 alemtuzumab Campath 63 metastatic renal cell 63 remission induction 63 relapsed ovarian cancer 63 lymphocytic leukemia 63 pegylated interferon alfa 2b 63 pCR 63 Rituxan rituximab 63 conventional DMARDs 63 idiopathic thrombocytopenic purpura 63 G#DT 63 cisplatin resistant 63 saline placebo 63 NovoTTF 63 interferon IFN 63 HuMax 63 bevacizumab Avastin ® 63 hematologic abnormalities 63 localized renal 63 FOLFIRI 63 mertansine 63 YONDELIS 63 refractory ovarian cancer 63 pertuzumab 63 etoposide 63 thyroid carcinoma 63 mTOR inhibitors 63 cytoreduction 63 reteplase 63 unresectable tumors 63 #mg BID [003] 63 mg m² 63 Patients Treated With 63 viral kinetics 63 inhibitor RG# 63 Idiopathic Pulmonary Fibrosis 63 basal cell carcinoma BCC 63 generation purine nucleoside 63 metastatic RCC 63 Vandetanib 63 metastatic renal 63 basiliximab 63 IV NSCLC 63 teriflunomide 63 Myelofibrosis 63 IIIA NSCLC 63 IgG1 monoclonal antibody 63 mcg QD 63 Sudhir Agrawal D.Phil 63 PEGylated Fab fragment 63 ABCB1 63 multikinase inhibitor 63 total thyroidectomy 63 Apolipoprotein B 63 topically administered 63 patients evaluable 63 neutropenia dehydration dyspnea 63 IIIb 63 oral allopurinol 63 Hematologic 63 Cloretazine 63 gemcitabine Gemzar 63 cinacalcet 63 Zarnestra 63 non metastatic osteosarcoma 63 paclitaxel cisplatin 63 breast carcinomas 63 low dose dexamethasone 63 IL 1ß 63 blastic phase 63 Aptivus ® 63 leucopenia 63 adjuvant cisplatin 63 Mycophenolate Mofetil 63 brivaracetam 63 Alkeran 63 Atypical Hemolytic Uremic Syndrome 63 Kinoid 63 lymphomas leukemias 63 PROSTVAC VF 63 endoscopic remission 63 anti PlGF 63 Phase Ib II 63 5FU 63 μg ml 63 renal tumors 63 epirubicin 63 ALT elevation 63 trastuzumab Herceptin ® 63 esophageal candidiasis 63 T1a 63 evaluable patients 63 â ‰ ¥ 63 pancreatic prostate 63 injected subcutaneously 63 epithelial ovarian 63 HBeAg 63 Cimzia TM 63 cutaneous melanoma 63 Newly Diagnosed Multiple Myeloma 63 Chronic Myelogenous Leukemia CML 63 recurrent epithelial ovarian 63 DLTs 63 neoadjuvant 63 murine model 63 plus DOXIL 63 definite stent thrombosis 63 -#.# log# 63 tuberous sclerosis TS 63 Peg IFN 63 FOLFOX regimen 63 ibandronate 63 advanced metastatic renal 63 PF # [002] 63 Luteinizing Hormone Releasing Hormone 62 tipranavir r 62 TRAIL R1 62 Telintra 62 imipenem 62 Panzem R NCD 62 olmesartan 62 Adjuvant Treatment 62 debulking surgery 62 CR CRu 62 extranodal 62 leuprorelin 62 A1PI 62 hypomethylating agents 62 tipifarnib 62 interferon alfa 2a 62 Capecitabine 62 PANVAC VF 62 Epidermal Growth Factor Receptor 62 TASKi2 62 B CLL 62 REYATAZ r arm 62 interferon ribavirin 62 endometrioid 62 budesonide foam 62 ALN HPN 62 cilengitide 62 HCV replicon 62 febrile neutropenia 62 HBeAg positive chronic hepatitis 62 Pegasys ® 62 Eli Lilly Gemzar 62 untreated metastatic colorectal 62 5-fluorouracil/leucovorin 62 CIN2 + 62 insulin glulisine 62 nonsmall cell lung cancer 62 Acute Coronary Syndromes ACS 62 ERalpha 62 plus methotrexate 62 BCG refractory 62 omacetaxine mepesuccinate 62 Platinol ® cisplatin 62 smoldering myeloma 62 Tesmilifene 62 neutrophil count 62 prostatic adenocarcinoma 62 patients undergoing CABG 62 methotrexate monotherapy 62 AVASTIN 62 DOXIL ® 62 pmol L 62 Proleukin 62 BRIM2 62 KRAS mutant tumors 62 Fluorouracil 62 relapsed AML 62 fallopian tube cancers 62 mg TID 62 trans retinoic acid 62 complete cytogenetic 62 prostate cancer CaP 62 vinca alkaloid 62 paclitaxel Taxol 62 Chronic lymphocytic leukemia 62 multicenter Phase II 62 paclitaxel Taxol R 62 Median PFS 62 Protease Inhibitors 62 interferon α 62 surgically resected 62 Erlotinib 62 mg q#h 62 tryptase 62 locoregional 62 lipid lowering agents 62 fluvastatin 62 gastrointestinal stromal tumors GIST 62 metastatic colorectal carcinoma 62 candidemia 62 adjuvant tamoxifen 62 Zavesca R 62 leukaemias 62 evaluating REVLIMID 62 cisplatin vinorelbine 62 huC# DM4 62 Noxafil 62 cholangiocarcinoma 62 docetaxel Taxotere 62 hypophosphatemia 62 metaglidasen 62 GLIADEL R Wafer 62 tiuxetan 62 squamous 62 temsirolimus 62 FDG PET imaging 62 RezularTM 62 Antiangiogenic 62 de novo AML 62 mapatumumab 62 Natalizumab 62 colorectal cancer liver metastases 62 refractory indolent non 62 overt nephropathy 62 doxorubicin docetaxel 62 corticosteroid dose 62 M2 subunit 62 BR.# 62 Intravitreal 62 FOLFOX chemotherapy 62 Interferon Beta 62 ORENCIA ® 62 ascending dose 62 Evoltra ® 62 Gliadel Wafer 62 ALT flares 62 HER2 amplification 62 EGFR expressing 62 refractory chronic myeloid 62 superficial basal cell carcinoma 62 DAPT 62 enterococcal 62 lung pancreatic 62 sunitinib Sutent ® 62 Solid Tumors criteria 62 Daclizumab 62 corticosteroid dexamethasone 62 immunomodulatory therapy 62 anaplastic astrocytomas 62 Naive Patients 62 MAGE A3 62 Nexavar tablets 62 Proxinium TM 62 TPV r 62 primary hypercholesterolemia 62 mg BID dose 62 curative resection 62 Monoclonal antibody 62 proteasome inhibitor 62 Vicinium TM 62 graft dysfunction 62 systemic anaplastic large 62 FLT3 62 IL# PE#QQR 62 golimumab CNTO 62 QD dosing 62 Pivotal Phase III 62 mCi kg 62 BRAF V#E 62 refractory CTCL 62 ug kg 62 colorectal liver metastases 62 GAMMAGARD 62 pegylated liposomal doxorubicin PLD 62 μmol L 62 abiraterone acetate 62 Randomized Phase 62 hepatic enzymes 62 Peginterferon Alfa 2a 62 CYT# QbG# 62 hypomethylating agent 62 #Gy 62 pyrazinamide 62 malignant lymphomas 62 investigational monoclonal antibody 62 relapsed refractory AML 62 Elitek 62 CD3 monoclonal antibody 62 PEGylated interferon beta 1a 62 Tofacitinib 62 PEGINTRON TM 62 null responder 62 visilizumab 62 #I TM# 62 histone deacetylase inhibitor 62 Phase 1b clinical trials 62 SSc 62 Relapsed Refractory Multiple Myeloma 62 antigen CD# 62 colorectal carcinomas 62 somatostatin analogue 62 HER2 overexpression 62 peginterferon alfa 2a #KD 62 HLA A2 62 nondiabetic patients 62 vinorelbine tartrate 62 LUX Lung 62 reduce serum phosphate 62 cervical intraepithelial neoplasia 62 mitoxantrone 62 neratinib 62 Pegylated Liposomal Doxorubicin 62 alanine aminotransferase ALT 62 Metastatic Melanoma 62 Kahalalide F 62 interferon gamma 1b 62 Kinase Inhibitor 62 gastric adenocarcinoma 62 cytarabine daunorubicin 62 Thal Dex 62 selective modulator 62 rituximab refractory 62 prostate cancer mCRPC 62 Sutent sunitinib 62 Anaplastic 62 chronic immune thrombocytopenic 62 targeting CD# 62 DFMO 62 Surgical resection 62 immune modulating 62 mg/m2 IV 62 refractory metastatic 62 xenograft models 62 Genentech Rituxan 62 seminal vesicle invasion 62 romiplostim 62 ER CHOP 62 Paraplatin ® carboplatin 62 rALLy 62 landmark ATHENA trial 62 adefovir dipivoxil 62 Annamycin 62 irreversible inhibitor 62 leukocyte count 62 herpetic keratitis 62 oral prodrug 62 JAK2 V#F 62 HDAC Inhibitor 62 docetaxel chemotherapy 62 decitabine 62 subcutaneously administered 62 myeloproliferative neoplasms 62 Anthracycline 62 trastuzumab DM1 62 Bosutinib 62 EGFR TKI 62 BAL# [002] 62 HNSCC 62 SIR Spheres 62 Aclidinium 62 Tarceva erlotinib 62 Darusentan 62 lenalidomide Revlimid 62 HQK 62 relapsed multiple myeloma 62 mycophenolic acid 62 CLARITY study 62 riociguat 62 Factor VIIa 62 Arzerra ofatumumab 62 Patients Receiving 62 fluorouracil 62 phase Ib 62 mTOR mammalian target 62 T#I [002] 62 CIN3 62 IFN beta 62 Initiated Phase 62 bortezomib Velcade 62 dose cytarabine 62 cGy 62 UPLYSO 62 visceral metastases 62 pouchitis 62 targeted antifolate 62 Neulasta R 62 DOXIL 62 stage IIIA 62 refractory gastrointestinal stromal 62 XIENCE V PROMUS Stent 62 FOR FURTHER INFORMATION ABOUT 62 colorectal carcinoma 62 dalteparin 62 tarenflurbil 62 bevacizumab Avastin R 62 polycythemia vera PV 62 randomized multicenter trial 62 measurable tumor regressions 62 ORENCIA R 62 gamma secretase inhibitor 62 Virulizin ® 62 Oxypurinol 62 CD# CD# 62 metastatic castration resistant 62 Torisel 62 Oral Fingolimod 62 LymphoStat B belimumab 62 refractory prostate cancer 62 TNF α 62 Torisel temsirolimus 62 PEG SN# 62 alvespimycin 62 Zemplar Capsules 62 Antiviral Therapy 62 sitaxsentan 62 Lenocta 62 mutated K ras 62 PNP inhibitor 62 gastrointestinal stromal tumors 61 coronary stenosis 61 resectable 61 receiving VICTRELIS 61 aspirin clopidogrel 61 intraepithelial neoplasia 61 mucinous 61 Rituxan MabThera 61 exocrine pancreatic insufficiency EPI 61 BCR ABL inhibitor 61 talabostat 61 peritumoral brain edema 61 aprepitant 61 situ CIS 61 Pegasys plus Copegus 61 Orally administered 61 #mg/m# [002] 61 #mg QD [001] 61 mg kg cohorts 61 HSCT 61 mg administered orally 61 ritonavir boosted lopinavir 61 axitinib 61 XL# SAR# 61 q#h 61 RhuDex R 61 Endometrial 61 cytogenic 61 #mg/day [002] 61 2 inhibitor CYT# 61 Hodgkin lymphoma NHL 61 iniparib BSI 61 R abatacept 61 surgically resectable 61 ularitide 61 Meets Primary Endpoint 61 cell acute lymphoblastic 61 #mg q8h 61 Amgen Neulasta ® 61 IOP lowering 61 PI3K/Akt pathway inhibitor 61 receptor blocker 61 elacytarabine 61 Tyrosine Kinase Inhibitors 61 idarubicin 61 angiotensin converting enzyme inhibitors 61 lactate dehydrogenase LDH 61 pharmacodynamic PD 61 mesangial 61 capecitabine Xeloda 61 thrombocytopenic 61 evaluating tivozanib 61 oropharyngeal candidiasis OPC 61 glioblastoma multiforme GBM 61 relapsing remitting MS RRMS 61 KSP inhibitor 61 cell malignancies 61 Pharmacodynamic 61 Neupogen ® 61 HRPC 61 PROSTVAC ®